

10. The compound of any one of claims 1 to 9, characterized in being partially or fully hydrated.
11. The compound of any one of claims 1 to 9, characterized in being anhydrous.
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 9, and a pharmaceutically acceptable carrier or excipient.
13. The pharmaceutical composition of claim 12, further comprising one to three additional therapeutic agents.
14. The pharmaceutical composition of claim 13, wherein the additional therapeutic agents are each anti-HIV drugs.
15. The pharmaceutical composition of claim 13 or claim 14, wherein the additional therapeutic agents are each independently selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, pharmacokinetic enhancers and other drugs for treating HIV.
16. The pharmaceutical composition of claim 13, wherein one of the one to three additional therapeutic agents is an HIV nucleoside inhibitor of reverse transcriptase.
17. The pharmaceutical composition of claim 12, further comprising tenofovir disoproxil fumarate and emtricitabine.
18. The pharmaceutical composition of claim 12, further comprising tenofovir alafenamide and emtricitabine.
19. The pharmaceutical composition of claim 12, further comprising tenofovir alafenamide fumarate and emtricitabine.